BridgeBio Pharma to Participate in September Investor Events

Rhea-AI Summary

BridgeBio Pharma, Inc. (Nasdaq: BBIO) will participate in several investor conferences, showcasing its commitment to genetic diseases and cancers. Key events include Citi’s 17th Annual BioPharma Conference on September 7 at 8:50 am ET, Morgan Stanley Global Healthcare Conference on September 13 at 7:20 am ET, and Baird Global Healthcare Conference on September 14 at 12:50 pm ET. Live webcasts will be available on BridgeBio’s website, with replays accessible for 90 days post-event. The company focuses on delivering transformative medicines through extensive R&D efforts.

PALO ALTO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: 

• Citi’s 17th Annual BioPharma Conference, Boston, MA: September 7^th at 8:50 am ET 
• Morgan Stanley Global Healthcare Conference, New York, NY: September 13^th at 7:20 am ET 
• Baird Global Healthcare Conference, New York, NY: September 14^th at 12:50 pm ET 
• H.C. Wainwright 24th Annual Global Investment Conference, New York, NY: September 14^th at 11:30 am ET
• Cantor Fitzgerald’s Genetic Medicines Conference, New York, NY: September 15^th
• Jefferies Genetic Cell and Medicine Summit, New York, NY: September 29^th
• Biotech South Beach, Miami, FL: September 29^th
  

To access the live webcast of BridgeBio’s presentations, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event. 

About BridgeBio Pharma, Inc. 
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter. 

BridgeBio Contact:
Grace Rauh
Grace.rauh@bridgebio.com
(917) 232-5478

FAQ

When is BridgeBio's presentation at Citi’s 17th Annual BioPharma Conference?

BridgeBio will present at Citi’s 17th Annual BioPharma Conference on September 7 at 8:50 am ET.

What is the date of the Morgan Stanley Global Healthcare Conference for BridgeBio?

BridgeBio will participate in the Morgan Stanley Global Healthcare Conference on September 13 at 7:20 am ET.

What conferences will BridgeBio attend in September 2022?

BridgeBio will attend several conferences in September 2022, including Baird Global Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference on September 14.

How can I access BridgeBio's investor conference presentations?

Live webcasts of BridgeBio's presentations can be accessed on the 'Events' page within the Investors section of their website.

What is the focus of BridgeBio Pharma, Inc.?

BridgeBio focuses on developing transformative medicines targeting genetic diseases and cancers.